Authorisation no cure to cartel risks posed by pharmaceutical patent settlement agreements
29 August 2022
Failed authorisation application likely to create difficulties for pharmaceutical settlement agreements in Australia
Read on
pay for delay
Patently uncertain: developments in pay-for-delay agreements in Australia
11 June 2020
Pay-for-delay pharmaceutical agreements have attracted scrutiny from regulators in the US and EU and are at greater risk of Australian regulatory attention
Read on
No more delay on reverse payments
11 January 2013
US Supreme Court to hear dispute over the legality of ‘pay-for-delay’ or reverse-payment agreements between patent holders and generic manufacturers
Read on